Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma.

This study provides a stratification based on the sexual differences in GBM, which associates the poor prognosis with the presence of immunosuppressive myeloid cells in the necrotic areas. This new stratification could change the current prognosis of GBM and identifies those who respond to BVZ treatment.